Key result
Gut microbiota modulation via probiotics, fiber, metformin, and SGLT2 inhibitors improves metabolic control in T2D.
Why the study?
The gut microbiota plays a key role in type 2 diabetes mellitus pathophysiology, and this study aimed to analyze its influence on pharmacological and dietary treatments based on current scientific evidence.
Do interventions that modulate the gut microbiome improve glucose parameters and metabolic complications in patients with type 2 diabetes mellitus?
Do interventions that modulate the gut microbiome improve glucose parameters and metabolic complications in patients with type 2 diabetes mellitus?
Modulation of the gut microbiota through diet, probiotics, and specific pharmacological agents represents a promising complementary therapeutic strategy for improving metabolic control in type 2 diabetes mellitus.
Supports microbiome modulation as adjunct in T2DM care; confirms and extends prior evidence on dysbiosis and metabolic outcomes.
Type 2 diabetes mellitus (T2DM) is a complex metabolic disease in whose pathophysiology the gut microbiota plays a key role, influencing systemic inflammation, insulin sensitivity, and glycemic homeostasis, thus conditioning the response to clinical and dietary treatments. The objective of this study was to analyze the influence of the gut microbiota on the pharmacological and dietary treatment of T2DM based on current scientific evidence. This systematic review, conducted according to the 2020 PRISMA guidelines, analyzed 27 studies published between 2014 and 2024, identifying that gut dysbiosis, characterized by a reduction in beneficial bacteria and an increase in pro-inflammatory species, is associated with poorer metabolic control in patients with T2DM. The most effective interventions included probiotics, prebiotics, synbiotics, high-fiber diets, and drugs with microbiota-modulating effects, such as metformin and SGLT2 inhibitors. Evidence suggests that modulation of the gut microbiota represents a promising complementary therapeutic strategy; however, methodological limitations still exist, highlighting the need for more robust clinical studies to support its widespread application.
No takes yet. Share an insight, caveat, or question.
Cevallos et al. (2026) studied this question. Gut microbiota modulation via probiotics, high-fiber diets, metformin, and SGLT2 inhibitors improves metabolic control in type 2 diabetes patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: